Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Dec. 09, 2016 --

What: 
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, will visit the Nasdaq MarketSite in Times Square, in celebration of its 5 year listing anniversary.

In honor of the occasion, Gary S. Jacob, Ph.D., Chairman of the Board and CEO, will ring the Closing Bell. 

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Monday, December 12, 2016 – 3:45 p.m. to 4:00 p.m. ET           

Synergy Media Contact:
Gem Hopkins
212-297-0020
[email protected]

Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Closing Bell will be available at: 
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: 
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice. 

About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. Synergy discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform that includes two lead product candidates – plecanatide and dolcanatide. Plecanatide is Synergy’s first uroguanylin analog currently being evaluated for use as a once-daily tablet for chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide is Synergy’s second uroguanylin analog currently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com  

-NDAQA-